Regulatory Bayer wins MHRA approval for Kerendia in heart failure PharmaTimesNew authorisation offers additional option for patients with lvef 40%RegulatoryCardiovascularRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) PharmaTimes New authorisation offers additional option for patients with lvef 40% RegulatoryCardiovascularRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumorsNext: FDA hands another rejection to Replimune’s melanoma therapy Related Stories Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients pharminent June 2, 2026 Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026 Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026
